NHS Fife Guidelines for Benzodiazepine Prescribing in Benzodiazepine Dependence

Total Page:16

File Type:pdf, Size:1020Kb

NHS Fife Guidelines for Benzodiazepine Prescribing in Benzodiazepine Dependence NHS Fife Guidelines for Benzodiazepine Prescribing in Benzodiazepine Dependence Dr. A. Baldacchino, Liz. Hutchings, Addiction Services Issued: April 2013 Review Date: April 2016 1 Approved by NHS Fife ADTC on behalf of NHS Fife Date June 2013 Contents Flowchart for Benzodiazepine Withdrawal ……………………………………………………………3 Establishing type of dependence. ........................................................................................... 4 Assessment of Benzodiazepine Dependence .............................................................................. 5 Management of dependence in therapeutic dose users ........................................................... 6 Management of dependence in prescribed high dose users. ................................................... 7 Management of dependence in illicit and recreational users. .................................................. 8 Psychological support. ................................................................................................................. 9 Pharmacological support............................................................................................................ 10 Appendices Appendix 1 Example Patient Letter (regular user) ................................................. 11 Appendix 2 Information leaflets and advice from the internet ................................ 13 Appendix 3 DRUG DIARY ..................................................................................... 14 Appendix 4 Benzodiazepine conversion table ....................................................... 15 Appendix 5 Withdrawal regimes for therapeutic dose users ................................. 16 Appendix 6 Withdrawal regimes for high dose users ............................................ 18 Appendix 7 Self-help guides for psychological support ......................................... 20 Dr. A. Baldacchino, Liz. Hutchings, Addiction Services Issued: April 2013 Review Date: April 2016 2 Approved by NHS Fife ADTC on behalf of NHS Fife Date June 2013 Flowchart for Benzodiazepine Withdrawal Patient taking benzodiazepine Assess. Establish dependence and pattern of usage Prescribed therapeutic dose Prescribed high dose Recreational high dose and dependence dependence abuse Monitor benzodiazepine use for Complete drug diary for at 2 3 months & complete at least least weeks two drug screens. Establish boundaries, set goals Is patient topping up Is minimum intervention prescription with illicitly obtained appropriate? Patient ready to reduce usage? benzodiazepine? Yes No No Yes Yes No Advise self-reduction of illicitly Continue to support reduction obtained benzodiazepine to Letter and FAQs using motivational interviewing. prescribed or therapeutic level. Do not Brief intervention Consider referral to prescribe doses of diazepam to Self-help booklet DAPL/FIRST/Psychology compensate for illicitly obtained drugs Agree gradual dose reduction converting to diazepam with twice daily Yes Patient reduced use to 30-40mg No dosing if appropriate. equivalent diazepam? Prescribe 2mg or 5mg diazepam only Reduce daily dose by about 1/8th (range 1/10th to ¼) every 2 or 3 weeks Withdrawal Symptoms? No Yes Maintain at present dose until symptoms improve-avoid increasing the dosage again Continue reduction at agreed Address any underlying mental rate health problems offering psychological or pharmacological support Renegotiate rate of reduction if required STOP COMPLETELY (Time needed can vary from 4 weeks to a year or more) Dr. A. Baldacchino, Liz. Hutchings, Addiction Services Issued: April 2013 Review Date: April 2016 3 Approved by NHS Fife ADTC on behalf of NHS Fife Date June 2013 Following the introduction of benzodiazepines in the 1960s as the treatment of choice for anxiety and insomniaFife Guidelines and their widespread for Benzodiazepine use from the Prescribing1970s onwards in it Benzodiazepinehas been recognised Dependence that long term use can result in physical and psychological dependence as well as tolerance to their use. In addition to patients prescribed benzodiazepines the illicit use, particularly by opioid drug users is a major problem for users in and out of drug treatment. High doses of prescribed and illicit benzodiazepines are taken and users become extremely tolerant to the sedative effects. Benzodiazepine withdrawal syndrome is characterised by insomnia, anxiety, loss of appetite and body- weight, tremor, perspiration, tinnitus, and perceptual disturbances. Abrupt withdrawal may produce confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens. For this reason patients exhibiting dependence should undergo gradual withdrawal of the benzodiazepine. Establishing type of dependence. Patients may exhibit dependency on a therapeutic dose or non-therapeutic dose – the latter group being subdivided into “prescribed high dose dependence” and “recreational high dose abuse and dependence” groups. Therapeutic Dose Prescribed High Dose Illicit and Recreational Use Dependence Dependence (eg ≥30mg diazepam) Dependence Characteristics of Therapeutic Dose Dependence – Patient may have: taken benzodiazepines in prescribed low doses for months or years. gradually come to “need” benzodiazepines in order to carry out normal activities of daily living. continued to take their medication even though original indication has disappeared. experienced withdrawal symptoms when they try to reduce or stop the drugs. contacted the prescriber frequently to request repeat prescriptions. experienced anxiety if there is a delay to the next prescription. increased the dosage since the original prescription experienced anxiety symptoms, panics, agoraphobia, insomnia, depression and increasing physical symptoms despite continuing to take benzodiazepines. Characteristics of Prescribed High Dose Dependence – patient requiring ever larger doses may: try to persuade doctor to escalate doses and/or number of tablets on the prescription. present at hospital or register at further practices to obtain more tablets combine benzodiazepine misuse with excessive alcohol consumption or other sedative drugs be highly anxious, depressed or have personality disorder tend not to use illicit drugs, but may obtain benzodiazepines from relatives or acquaintances. Characteristics of Recreational High Dose Abuse & Dependence – Often develops as polydrug abusers attempt to enhance the effect of opioids or to “come down” from stimulants. A very high tolerance develops making it difficult to detect the actual scale of drug consumption. Users may be taking well in excess of 100mg daily in a single dose to maximise the effect. There may be a concurrent alcohol problem and the user may have been introduced to benzodiazepines during previous alcohol detoxification Dr. A. Baldacchino, Liz. Hutchings, Addiction Services Issued: April 2013 Review Date: April 2016 4 Approved by NHS Fife ADTC on behalf of NHS Fife Date June 2013 Assessment of Benzodiazepine Dependence 1. Establish PATTERN of benzodiazepine usage 2. Establish DEPENDENCE if 3 or more or the following are present in the same 12-month period: Date of onset of usage ……………………………… 3 to 5 indicators – mild to moderate dependence Benzodiazepines used ………………………………. 5 to 7 indicators – moderate to severe dependence i) Tolerance – a need for increased amounts to achieve desired effect OR Average daily dose and dose intervals …………….. - diminished effect with continued use of same amount Previous successful withdrawal from use? ………… ii) Withdrawal – previous attempts to cut down result in withdrawal symptoms OR - substance is taken to prevent withdrawal symptoms If yes, longest period of abstinence? ……………… iii) Substance taken in larger amounts or over longer period than originally intended Any other drug or alcohol used?.............................. iv) Persistent desire or unsuccessful effort to cut down or control use v) Great deal of time spent obtaining substance or recovering from its effects vi) Important activities (social, work related or recreational) given up or reduced vii) Continued use of drug despite clear evidence of harmful effects 4. Establish CATEGORY of dependence: DSM-IV Diagnostic Criteria for Substance Dependence Therapeutic Dose Dependence Started for a reason and continued 3. Additional considerations (to inform but not prevent detox): High Dose Dependence Concomitant severe medical or psychiatric illness Started as a prescription and then escalated No other drug or alcohol problems History of severe withdrawal (including PROVEN history of seizures) Recreational High Dose Abuse & Dependence Completion of drug diary (for at least 2 weeks, up to 3 months may be appropriate) Used and abused by people who use drugs: illicit, POM or OTC and/or alcohol Confirmation of dependence by drug screening (urine but consider oral fluid) See page 4 for more detail Level of motivation to change Dr. A. Baldacchino, Liz. Hutchings, Addiction Services Issued: April 2013 Review Date: April 2016 5 Approved by NHS Fife ADTC on behalf of NHS Fife Date June 2013 Management of dependence in therapeutic dose users Management can include minimal interventions, gradual dose reduction and gradual dose reduction with additional psychological support. Minimal interventions (1 and 2 below) are suitable in early/mild dependence. 1. Write to the patient: explain problems associated with long-term benzodiazepine use and the need to reduce their prescription encouraging a gradual reduction or cessation if possible. (appx 1) 2. Brief Intervention: Simple
Recommended publications
  • The Diagnosis and Management of Benzodiazepine Dependence Heather Ashton
    The diagnosis and management of benzodiazepine dependence Heather Ashton Purpose of review Abbreviation Despite repeated recommendations to limit GABA g -aminobutyric acid benzodiazepines to short-term use (2–4 weeks), doctors worldwide are still prescribing them for months or years. # 2005 Lippincott Williams & Wilkins This over-prescribing has resulted in large populations of 0951-7367 long-term users who have become dependent on benzodiazepines and has also led to leakage of benzodiazepines into the illicit drug market. This review Introduction outlines the risks of long-term benzodiazepine use, gives Since their introduction in the 1950s, benzodiazepines guidelines on the management of benzodiazepine appear to have passed their zenith of medical popularity. withdrawal and suggests ways in which dependence can However, they are still prescribed excessively and often be prevented. inappropriately. With their reputation perhaps approach- Recent findings ing a nadir, at least as prescribed medications for Recent literature shows that benzodiazepines have all the long-term use, it is timely to review approaches to the characteristics of drugs of dependence and that they are diagnosis and management of dependence on these inappropriately prescribed for many patients, including drugs. those with physical and psychiatric problems, elderly residents of care homes and those with comorbid alcohol The benzodiazepine bonanza and substance abuse. Many trials have investigated In the late 1970s benzodiazepines became the most methods of benzodiazepine
    [Show full text]
  • The BENZODIAZEPINE TOOLKIT
    the BENZODIAZEPINE TOOLKIT By Reconnexion Acknowledgements The 2018 edition of the Beyond Benzodiazepines toolkit has been revised from the 1997 original updated in 2000 and again in 2010. For this version thanks to Erin Oldenhof, James Szeto and Jane Anderson-Wurf. The 2010 version was updated by Tomi Redman and Gwenda Cannard with additional material by Janet Haynes, Jo Marston and Laurence Hennessey. Reconnexion (now a service of EACH) is grateful for the support of ExxonMobil Australia for enabling the revision and update on the 2010 manual. The 1997 original manual was written by Elin Ree and supported by ExxonMobil for which Reconnexion is grateful. Thanks to the Psychotropic Expert Group, Therapeutic Guidelines Limited for permission to use the Comparative Information for Benzodiazepines, Zolpidem and Zopiclone table in Chapter Four. Updates, revisions and feedback retained in the revised version were provided by Therese Barry (Alcohol & Drug Counsellor, Western Region Community Health Centre), Dr Robert Cummins (Deakin University), Hilde Edward (Swinburne University), Lisa Frank (University of Melbourne), Melanie Hands (Project Manager, Drug & Alcohol Clinical Advisory Service, Turning Point Alcohol & Drug Centre), Terrie Hollingsworth (Counsellor, Sunbury Community Health), Dr Peter Johnson (GP), Dr Len Klimans (Chemical Dependency Unit, Royal Women’s Hospital), Dr Nic Lintzeris (Turning Point Alcohol & Drug Centre), Dr Mike McDonough (Consultant, St. Vincent’s Alcohol & Drug Program, Western General Hospital Alcohol & Drug Program), Peter McManus (Secretary, Drug Utilisation Sub Committee, Pharmaceutical Benefits Scheme, Department of Health & Ageing), Dr Robert Moulds (Director, Department of Clinical Pharmacology & Therapeutics, Royal Melbourne Hospital), Jackie Shaw (Manager, Depaul House, St Vincent’s Hospital, Melbourne), Lyn Walker (Manager, CASA House, Royal Women’s Hospital, Melbourne) and Dr Sally Wilkins (North East Melbourne Psychiatric Services, Department of Human Services, Victoria).
    [Show full text]
  • Social Networking and Benzodiazepine Withdrawal: The
    Catherine M. Pittman, Ph.D. William Youngs, Ph.D. Elizabeth (Lisa) Karle, MLIS Saint Mary’s College Notre Dame, Indiana ADAA Conference April 5, 2013 No Disclosures. Thank you We would like to begin by expressing our thanks to all those who completed the survey and shared their experiences with us. We also owe a great debt to the founder of BenzoBuddies as well as a skilled technician assistant associated with the group. They provided invaluable advice and assistance, and without their help, the survey would not have been as valid or successful. Finally, we want to thank research assistant Carla Leal for her patient assistance in the creation and coding of the survey. Note: This survey was reviewed and approved by the Institutional Review Board at Saint Mary’s College. When individuals have difficulty with anxiety, what is the most typical response? Often they approach their family doctor, who attempts to treat the anxiety or refers them to a psychiatrist. In either case, it is very likely that a medical (psychopharmalogical) solution may be offered. The solution offered is often benzodiazepines. The United States has the highest rate of benzodiazepine prescription in the world (Rivas- Vazquez, 2003). If the person is prescribed benzodiazepines, short term relief is obtained, but tolerance develops and increasing dosages may be required. Dependence on benzodiazepines is very likely, and how do we help individuals facing benzodiazepine dependence? The truth is we don’t. And this is the reason that Social Networking is important to them.
    [Show full text]
  • Benzodiazepine Equivalence Table
    benzo.org.uk : Benzodiazepine Equivalence Table http://www.benzo.org.uk/bzequiv.htm « back exit frame back to frame www.benzo.org.uk » BENZODIAZEPINE EQUIVALENCE TABLE (Benzodiazepine Equivalency Table) Revised April 2007 This Benzodiazepine Equivalence Table is based on the extensive research and clinical experience of Professor C Heather Ashton , DM, FRCP, Emeritus Professor of Clinical Psychopharmacology at the University of Newcastle upon Tyne, England. Sources: NRHA Drug Newsletter , April 1985 and Benzodiazepines: How they Work & How to Withdraw (The Ashton Manual ), 2002. The approximate equivalent doses to 10mg diazepam (Valium) are given. For a discussion of half-lives and equivalencies see also the Benzo FAQ document . 2 Approximately Half-life (hrs) Market Benzodiazepines 1 [active Equivalent Aim4 metabolite] Oral dosages (mg) 3 Alprazolam 6-12 0.5 a (Xanax, Xanor, Tafil) Bromazepam 10-20 5-6 a (Lexotan, Lexomil) Chlordiazepoxide 5-30 [36-200] 25 a (Librium) Clobazam 12-60 20 a,e (Frisium) 5 Clonazepam 18-50 0.5 a,e (Klonopin, Rivotril) 5 Clorazepate [36-200] 15 a (Tranxene) Diazepam 20-100 [36-200] 10 a (Valium) Estazolam 10-24 1-2 h (ProSom, Nuctalon) Flunitrazepam 18-26 [36-200] 1 h (Rohypnol) Flurazepam [40-250] 15-30 h (Dalmane) Halazepam [30-100] 20 a (Paxipam) 1 sur 3 01/02/2010 18:46 benzo.org.uk : Benzodiazepine Equivalence Table http://www.benzo.org.uk/bzequiv.htm Ketazolam 30-100 [36-200] 15-30 a (Anxon) Loprazolam 6-12 1-2 h (Dormonoct) Lorazepam 10-20 1 a (Ativan, Temesta, Tavor) Lormetazepam 10-12 1-2 h (Noctamid) Medazepam 36-200 10 a (Nobrium) Nitrazepam 15-38 10 h (Mogadon) Nordazepam 36-200 10 a (Nordaz, Calmday) Oxazepam (Serax, Serenid, 4-15 20 a Serepax, Seresta) Prazepam [36-200] 10-20 a (Centrax, Lysanxia) Quazepam (Doral) 25-100 20 h Temazepam (Restoril, Normison, 8-22 20 h Euhypnos) Triazolam 2 0.5 h (Halcion) Non-benzodiazepines with similar effects 1, 6 Zaleplon 2 20 h (Sonata) Zolpidem (Ambien, Stilnoct, 2 20 h Stilnox) Zopiclone 5-6 15 h (Zimovane, Imovane) Eszopiclone 6 3 h (Lunesta) (9 in elderly) 1.
    [Show full text]
  • Pharmacology and Effects of Cannabis: a Brief Review
    BRITISH JOURNAL OF PSYCHIATRY $2001), 178, 101^106 Pharmacology and effects of cannabis: Health Organization, 1997; Solowij, 1998). This fact is important since the ef- abriefreview{{ fects of THC are dose-related and most of the research on cannabis was carried out in the 1970s using doses of 5±25 mg THC C. HEATHER ASHTON !World Health Organization, 1997). Gold !1991, p. 356) remarks: ``This single fact has made obsolete much of what we once knew about the risks and consequences of marijuana use''. In the UK at present, many recreational users grow their own supplies of high- Background Increasing prevalence of Herbal cannabis contains over 400 com- potency cannabis !exact details of how to recreational cannabis use among the pounds including over 60 cannabinoids, grow it can be obtained on the internet). which are aryl-substituted meroterpenes Another main source is imports from Holland young population has stimulated debate unique to the plant genus CannabisCannabis..The The !also high-potency) and home growers can ononthe the possible effects of acute andlong-and long- pharmacology of most of the cannabinoids obtain seeds in Amsterdam at £10±£50 term use.use.term is largely unknown but the most potent for 10 seeds, depending on potency. Canna- psychoactive agent, DD99-tetrahydrocannabi- bis can be smoked as joints, from pipes, or Aims TohighlightrecentknowledgeofTohighlightrecent knowledge of nol !nol!DD99-THC, or THC), has been isolated, from `buckets', by inhaling from a mass of mechanisms of action, effects on synthesised and much studied. Other plant plant or resin ignited in a sawn-off plastic psychomotor and cognitive performance, cannabinoids include DD88-THC, cannabinol bottle.
    [Show full text]
  • Perils in Benzodiazepine Withdrawal: Case Report
    EJMED, European Journal of Medical and Health Sciences Vol. 2, No. 3, June 2020 Perils in Benzodiazepine Withdrawal: Case Report V. F. H Macfarlane, L. J. Moore obstructive sleep apnea resolved on repeat testing after Abstract — The discovery that clonazepam prescribed for conversion to lorazepam. Lorazepam was substituted the treatment of migraines caused obstructive sleep apnea led because it is short acting with no active metabolites and is to a rapid taper of clonazepam and substitution of lorazepam. considered favorable for use in the elderly. A very rapid Lack of accurate knowledge about the different pharmacokinetics and actions of different benzodiazepines at conversion and an inadequate substitution were made and GABA-A receptors and the risks associated with rapid the patient developed multiple physical symptoms. It took benzodiazepine withdrawal resulted in the development of the more than four months before an addiction specialist benzodiazepine protracted withdrawal syndrome. Moderately instituted appropriate treatment with a low dose of diazepam severe disability continued after 2 years. Insufficient and recognised the symptoms were due to the knowledge about benzodiazepines and their withdrawal is a benzodiazepine protracted withdrawal syndrome. None of serious problem as doctors across the world are under extreme pressure to stop prescribing them but do not have an the patient’s previous doctors had any understanding of understanding of the potential perils involved. The benzodiazepine withdrawal or recognised the challenges pathophysiology of protracted withdrawal syndrome remains associated with conversion of one benzodiazepine for poorly understood and there is no recognised treatment. another. A very slow titration of 0.5 to 1 mg diazepam every Information about appropriate management of withdrawal 2-3 months was recommended by the addiction specialist; and the protracted withdrawal syndrome are available on however, a new treating doctor reduced the dose of Professor Ashton’s website at www.benzo.org.uk.
    [Show full text]
  • Step by Step Guide to Reducing from Benzodiazepines
    STEP BY STEP GUIDE Reducing from Benzodiazepines & Recovery from Withdrawal 1 Table of Contents Introduction ........................................................................................................ ...3 List of Benzodiazepines .......................................................................................... 5 Dose Equivalents .................................................................................................... 6 Stabilising and Reducing the Dose ......................................................................... 7 Example of a Reduction Regime .......................................................................... 11 Benzodiazepine Withdrawal Symptoms .............................................................. 13 Management of Withdrawal Symptoms .............................................................. 14 Tips to Help with Withdrawal Symptoms ............................................................ 15 Suggestions for your Diet whilst withdrawing ..................................................... 17 Staying off Tranquillisers and Sleeping Pills ......................................................... 18 Relaxation ............................................................................................................. 19 Breathing Exercise ................................................................................................ 22 Resources for Further Assistance ......................................................................... 23 2 Introduction These
    [Show full text]
  • Risks of Dependence on Benzodiazepine Drugs: a Major Problem of Long Term Treatment
    Risks of dependence on benzodiazepine drugs: a major problem of long term treatment Heather Ashton BMJ: first published as 10.1136/bmj.298.6666.103 on 14 January 1989. Downloaded from Phlegmatic people dislike taking benzodiazepine drugs. In those with low'anxiety traits benzodiazepines Profiles of dependence on drugs are dysphoric and may paradoxically increase anxiety.' In normal subjects benzodiazepines improve perform- People who become dependent on drugs are suggested ance under experimental stress but worsen it under to be two different populations at the extremes of a conditions of low stress.2 Benzodiazepines relieve pre- normal distribution. Those who take drugs for pro- operative anxiety in patients with high anticipatory tection are anxious, have high scores for neuroticism but not in those with low anxiety.3 (N),46 17 are highly susceptible to punishment,'4 tender anxiety anticipatory minded, and socially compliant.4 Their preferred Thus like 0i receptor blocking agents benzodiazepines drugs are benzodiazepine tranquillosedatives, which require some underlying tone upon which to exert their they tend to take long term in low, prescribed doses. anxiolytic effects. In general, the greater the anxiety They are sensitive to withdrawal largely because of the greater the anxiolytic efficacy. their anxiety and poor abilities in coping with stress. It follows that most people who take benzodiazepines In contrast, those who take drugs for kicks have are anxious. In students a history of prescribed high scores for psychoticism (P),'7 are highly sensitive benzodiazepines correlates with a high anxiety trait.4 to reward,'4 impulsive, tough minded, antisocial, and Long term users likewise have high scores for neuroti- seek sensation.4 '7 They tend to abuse hard and soft cism.
    [Show full text]
  • Fife Guidelines for Benzodiazepine Prescribing in Benzodiazepine Dependence
    NHS Fife Guidelines for Benzodiazepine Prescribing in Benzodiazepine Dependence Dr. A. Baldacchino, Liz. Hutchings, Addiction Services Issued: April 2013 Review Date: April 2016 1 Approved by NHS Fife ADTC on behalf of NHS Fife Date June 2013 Contents Flowchart for Benzodiazepine Withdrawal ……………………………………………………………3 Establishing type of dependence. ...........................................................................................4 Assessment of Benzodiazepine Dependence..............................................................................5 Management of dependence in therapeutic dose users............................................................6 Management of dependence in prescribed high dose users. ...................................................7 Management of dependence in illicit and recreational users. ..................................................8 Psychological support. .................................................................................................................9 Pharmacological support............................................................................................................10 Appendices Appendix 1 Example Patient Letter (regular user).................................................11 Appendix 2 Information leaflets and advice from the internet................................13 Appendix 3 DRUG DIARY.....................................................................................14 Appendix 4 Benzodiazepine conversion table.......................................................15
    [Show full text]
  • Ashton-Manual.Pdf
    ! With full permission from relevant parties, Benzodiazepine Information Coalition (BIC) is offering this reprint of Dr. Heather Ashton’s benzodiazepine guide, aka the “Ashton Manual,” in PDF format solely for ease of printing, sharing, and accessibility by professionals and patients alike. With the exception of the updated contact and support list, this copy is identical to the original, completely unchanged and unedited, including the original medical disclaimer provided by benzo.org.uk where the manual was first published. BIC provides this copy solely for educational purposes and as a courtesy, bearing no responsibility for the contents of the manual or the outcomes of following it. www.benzoinfo.com Any use of materials contained within this manual including reproduction, modification, or republication without the prior permission of Professor C Heather Ashton is strictly prohibited. © Copyright Professor C Heather Ashton To purchase a bound copy of the manual please visit www.benzobookreview.com BENZODIAZEPINES: HOW THEY WORK AND HOW TO WITHDRAW (aka The Ashton Manual) • PROTOCOL FOR THE TREATMENT OF BENZODIAZEPINE WITHDRAWAL • Medical research information from a benzodiazepine withdrawal clinic Professor C Heather Ashton DM, FRCP Revised August 2002 • Ashton Manual Index Page • Contents Page • Introduction • Chapter I: The benzodiazepines: what they do in the body • Chapter II: How to withdraw from benzodiazepines after long-term use • Chapter II: Slow withdrawal schedules • Chapter III: Benzodiazepine withdrawal symptoms, acute & protracted CONTENTS PAGE THE ASHTON MANUAL SUPPLEMENT, APRIL 2011 IMPORTANT MESSAGE FROM PROFESSOR ASHTON, JANUARY 2007 FOREWORD TO REVISED EDITION, AUGUST 2002 FOREWORD 2001 ABOUT PROFESSOR C HEATHER ASHTON, DM, FRCP SUMMARY OF CONTENTS MEDICAL DISCLAIMER CHAPTER I.
    [Show full text]
  • Risks of Dependence on Benzodiazepine Drugs: a Major Problem of Long Term Treatment
    Risks of dependence on benzodiazepine drugs: a major problem of long term treatment Heather Ashton BMJ: first published as 10.1136/bmj.298.6666.103 on 14 January 1989. Downloaded from Phlegmatic people dislike taking benzodiazepine drugs. In those with low'anxiety traits benzodiazepines Profiles of dependence on drugs are dysphoric and may paradoxically increase anxiety.' In normal subjects benzodiazepines improve perform- People who become dependent on drugs are suggested ance under experimental stress but worsen it under to be two different populations at the extremes of a conditions of low stress.2 Benzodiazepines relieve pre- normal distribution. Those who take drugs for pro- operative anxiety in patients with high anticipatory tection are anxious, have high scores for neuroticism but not in those with low anxiety.3 (N),46 17 are highly susceptible to punishment,'4 tender anxiety anticipatory minded, and socially compliant.4 Their preferred Thus like 0i receptor blocking agents benzodiazepines drugs are benzodiazepine tranquillosedatives, which require some underlying tone upon which to exert their they tend to take long term in low, prescribed doses. anxiolytic effects. In general, the greater the anxiety They are sensitive to withdrawal largely because of the greater the anxiolytic efficacy. their anxiety and poor abilities in coping with stress. It follows that most people who take benzodiazepines In contrast, those who take drugs for kicks have are anxious. In students a history of prescribed high scores for psychoticism (P),'7 are highly sensitive benzodiazepines correlates with a high anxiety trait.4 to reward,'4 impulsive, tough minded, antisocial, and Long term users likewise have high scores for neuroti- seek sensation.4 '7 They tend to abuse hard and soft cism.
    [Show full text]
  • Guidance for the Use and Reduction of Misuse of Benzodiazepines and Other Hypnotics and Anxiolytics in General Practice
    Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice Chris Ford and Fergus Law Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice Chris Ford and Fergus Law with support from Jean-Claude Barjolin, Jo Betterton, Tom Carnwath, Clare Gerada, Steve Iliffe, Mick McKernan, Graham Parsons, Stephen Pick and Muriel Simmonte Final draft: July 2014 CONTENTS SUMMARY PART 1: SECTION 1: INTRODUCTION 1.1 Background 1.2 History of benzodiazepines and other hypnotics and anxiolytics 1.3 Prevalence of benzodiazepine use and other hypnotics and anxiolytics SECTION 2: CLINICAL PHARMACOLOGY 2.1 Properties and clinical actions 2.2 Speed of onset and peak effects 2.3 Duration of action 2.4 Metabolism 2.5 Mechanism of action 2.6 Tolerance 2.7 Equivalence SECTION 3: TREATMENT OF INSOMNIA AND ANXIETY 3.1 Insomnia, anxiety, panic disorder and related conditions 3.2 Practical prescribing SECTION 4: ADVERSE EFFECTS & PROBLEMS WITH, MANAGEMENT OF AND WITHDRAWAL FROM LONG-TERM USE 4.1 Specific problems with long-term use 4.2 Withdrawal from long-term use 4.3 Other pharmacological treatments that may sometimes be useful 4.4 Longer-term prescribing PART 2: SECTION 5: ADDITIONAL INFORMATION ABOUT CERTAIN GROUPS 5.1 People with mental illness 5.2 People who use alcohol 5.3 Involuntary addiction 5.4 People who use drugs 5.5 Women 5.6 Pregnant women, neonates and breast-feeding mothers 5.7 Parents and carers 5.8 Children and young people
    [Show full text]